{"product_id":"cytokine-therapies-isbn-9781573317832","title":"Cytokine Therapies","description":"Cytokines are protein messengers responsible for cellular communication with great therapeutic potential to control inflammatory and immune disorders such us cancer, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Despite the solid scientific rationale for this therapeutic promise, many cytokine-related therapies have failed to establish clinical utility.  \u003cp\u003eIn March 2009, international experts from academia, industry and government convened to discuss the scientific and clinical basis for the successes and failures of recombinant cytokines and cytokine antagonists as therapeutic agents, and possible strategies for improving their clinical success. This volume included extended versions of key presentations at the meeting.\u003c\/p\u003e \u003cp\u003eParticipants examined:\u003cbr\u003e • Improved methods for identifying disease targets\u003cbr\u003e • Alternative methods for enhancing and targeting cytokine delivery\u003cbr\u003e • Physicochemical modification of cytokines to prolong their bioavailability\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eNOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit \u003ca href=\"http:\/\/www.blackwellpublishing.com\/nyas\"\u003ewww.blackwellpublishing.com\/nyas\u003c\/a\u003e.\u003c\/p\u003e \u003cp\u003eACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (\u003ca href=\"http:\/\/www.nyas.org\/\"\u003ewww.nyas.org\u003c\/a\u003e). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit \u003ca href=\"http:\/\/www.nyas.org\/MemberCenter\/Join.aspx\"\u003ehttp:\/\/www.nyas.org\/MemberCenter\/Join.aspx\u003c\/a\u003e for more information about becoming a member.\u003c\/p\u003e An overview of cytokines and cytokine antagonists as therapeutic agents  1 \u003cp\u003ePharmacologic administration of interleukin-2: inducing a systemic autophagic syndrome? 14\u003c\/p\u003e \u003cp\u003ePerspective on potential clinical applications of recombinant human interleukin-7 28\u003c\/p\u003e \u003cp\u003eImmune modulation with interleukin-21 39\u003c\/p\u003e \u003cp\u003eClinical and immunologic basis of interferon therapy in melanoma 47\u003c\/p\u003e \u003cp\u003eHeterogeneous, longitudinally stable molecular signatures in response to interferon-beta 58\u003c\/p\u003e \u003cp\u003eClinical use of interferon-gamma 69\u003c\/p\u003e \u003cp\u003eInterferon lambda as a potential new therapeutic for hepatitis C 80\u003c\/p\u003e \u003cp\u003eCytokines as targets for anti-inflammatory agents 88\u003c\/p\u003e \u003cp\u003eUstekinumab: lessons learned from targeting interleukin-12\/23p40 in immune-mediated diseases 97\u003c\/p\u003e \u003cp\u003eBlocking interleukin-1 in rheumatic diseases: its initial disappointments and recent successes in the treatment of autoinflammatory diseases 111\u003c\/p\u003e \u003cp\u003eRilonacept: CAPS and beyond, a scientific journey 124\u003c\/p\u003e \u003cp\u003eActobiotics as a novel method for cytokine delivery: the interleukin-10 case 135\u003c\/p\u003e \u003cp\u003eHurdles and leaps for protein therapeutics: cytokines and inflammation 146\u003c\/p\u003e  \u003cp\u003e\u003cstrong\u003eRaymond P. Donnelly\u003c\/strong\u003e, Food and Drug Administration, Rockville, MD.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989020492005,"sku":"NP9781573317832","price":149.75,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781573317832.jpg?v=1761782466","url":"https:\/\/k12savings.com\/es\/products\/cytokine-therapies-isbn-9781573317832","provider":"K12savings","version":"1.0","type":"link"}